Cancer Genetics (NASDAQ:CGIX) target raised to $6.00, reported today by Rodman & Renshaw
- Updated: September 25, 2016
Reporting as possible upside of 2.41%, Rodman & Renshaw upped the price target of Cancer Genetics (NASDAQ:CGIX) to $6.00
Yesterday Cancer Genetics (NASDAQ:CGIX) traded -3.30% lower at $1.76. The company’s 50-day moving average is $2.08 and its 200-day moving average is $2.27. The last stock close price is down -22.42% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 45,135 shares of the stock were exchanged, down from an average trading volume of 97,747
See Chart Below
Cancer Genetics has a 52 week low of $1.72 and a 52 week high of $9.50 The company’s market cap is currently $0.
In addition to Rodman & Renshaw reporting its target price, a total of 3 firms have issued a report on the stock. The consensus target price is $8.42 with 2 firms rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Cancer Genetics (NASDAQ:CGIX)
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.